$HEM has finally received its intellectual property back

Hemostemix HEM presently possesses the entirety of the intellectual property, which involves all the HS 12-01 2nd phase trial data and all the verified information from Hemostemix Israel.
Beyond Technical AnalysisFundamental AnalysisstocknewsStockstraderstradingview

Clause de non-responsabilité